TP53 and myelodysplastic syndrome: Decitabine alone (a hypomethylating agent, similar to AZA) was able to produce a very high response rate (100%) in patients with AML or MDS carrying a TP53 mutation.421 This suggests that the therapeutic effect of the hypomethylating agent may be dominant in myeloid malignancies carrying TP53 mutations.